m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00528)
Name
Palomid-529
Synonyms
Palomid 529; 914913-88-5; P529; Palomid 529 (P529); 8-(1-Hydroxyethyl)-2-methoxy-3-((4-methoxybenzyl)oxy)-6H-benzo[c]chromen-6-one; SG 00529; SG-00529; P-529; 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one; UNII-XV9409EWG4; 6H-Dibenzo(b,d)pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-; 8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-6H-benzo[c]chromen-6-one; Palomid529; 6H-Dibenzo[b,d]pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-; 8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxybenzyl)oxy]-6H-benzo[c]chromen-6-one; RES-529; XV9409EWG4; Palomid 529,P529; cc-513; MLS006011187; Palomid 529 - P529; SCHEMBL290034; C22H26Cl2N2O8; CHEMBL2141712; EX-A254; QCR-215; SYN5215; BCPP000131; HMS3655L14; HMS3673G05; AMY22735; BCP02474; ABP000907; MFCD18633224; NSC775306; NSC801008; s2238; 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one; AKOS024463339; ACN-030389; BCP9001049; CCG-268719; CS-0258; DB12812; NSC-775306; NSC-801008; Palomid 529 (P529) /P529; SB16564; SG00529; 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-6h-dibenzo(b,d)pyran-6-one; NCGC00263125-01; NCGC00263125-10; AC-31523; AK160239; AS-16573; HY-14581; SMR004702956; AB0008147; SW219676-1; Y0291; W-5766; J-519339; Q27294013
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C24H22O6
InChI
1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3
InChIKey
YEAHTLOYHVWAKW-UHFFFAOYSA-N
PubChem CID
11998575
TTD Drug ID
DP17AI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Mammalian target of rapamycin complex 1 (mTORC1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). [2], [3]
RNA-binding motif protein 15 (RBM15)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The RNA-binding motif protein 15 (RBM15) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). [2], [3]
RNA-binding motif protein 15B (RBM15B)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The RNA-binding motif protein 15B (RBM15B) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). [2], [3]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). [2], [3]
Target of rapamycin complex 2 MAPKAP1 (MTORC2)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for Palomid-529. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Palomid-529 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). [2], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for Palomid-529. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Palomid-529 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). [2], [4]
References
Ref 1 Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation. Biosci Rep. 2021 Jan 29;41(1):BSR20200842. doi: 10.1042/BSR20200842.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 mTORC1-chaperonin CCT signaling regulates m(6)A RNA methylation to suppress autophagy. Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):e2021945118. doi: 10.1073/pnas.2021945118.
Ref 4 m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018 Sep;20(9):1074-1083. doi: 10.1038/s41556-018-0174-4. Epub 2018 Aug 27.